Keros Therapeutics (Keros Therapeutics) EBIT : $-152.99 Mil (TTM As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Keros Therapeutics EBIT?

Keros Therapeutics's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was $-40.24 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was $-152.99 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Keros Therapeutics's annualized ROC % for the quarter that ended in Dec. 2023 was -578.90%. Keros Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -836.35%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Keros Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -8.19%.

Keros Therapeutics EBIT Historical Data

The historical data trend for Keros Therapeutics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Keros Therapeutics EBIT Chart

Keros Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-12.33

-45.53

-56.73

-104.68

-152.99

Keros Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT	Get a 7-Day Free Trial															-29.72	-35.80	-37.51	-39.44	-40.24

Competitive Comparison of Keros Therapeutics's EBIT

For the Biotechnology subindustry, Keros Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Keros Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Keros Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Keros Therapeutics's EV-to-EBIT falls into.

Keros Therapeutics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-152.99 Mil.

Keros Therapeutics (NAS:KROS) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Keros Therapeutics's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	-176.22 * ( 1 - 0% )	/	( (28.937	+	31.944)	/ 2 )
=	-176.22	/	30.4405
=	-578.90 %

where

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	326.247	-	9.576	-	( 287.893	-	max(0, 16.701	-	304.435	+	287.893	))
=	28.937

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	370.025	-	15.161	-	( 331.147	-	max(0, 24.373	-	347.293	+	331.147	))
=	31.944

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Keros Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-160.972	/	( ( (19.026 + max(-0.44599999999999, 0))	+	(19.468 + max(-8.17, 0)) )	/	2 )
=	-160.972	/	( ( 19.026	+	19.468 )	/	2 )
=	-160.972	/	19.247
=	-836.35 %

where Working Capital is:

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	15.644)	-	(9.576	+	0	+	6.514)
=	-0.44599999999999

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.143	+	0	+	15.055)	-	(15.161	+	0	+	8.207)
=	-8.17

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Keros Therapeutics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	-152.992	/	1867.923
	=	-8.19 %

Keros Therapeutics EBIT Related Terms

Thank you for viewing the detailed overview of Keros Therapeutics's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Keros Therapeutics (Keros Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Keros Therapeutics Inc (NAS:KROS) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

1050 Waltham Street, Suite 302, Lexington, MA, USA, 02421

Website

https://www.kerostx.com

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

Executives

Keith Regnante	officer: Chief Financial Officer	733 CONCORD AVENUE, CAMBRIDGE MA 02138
Alpna Seth	director	614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413
Jennifer Lachey	officer: Chief Scientific Officer	C/O KEROS THERAPEUTICS, INC., 99 HAYDEN AVENUE, SUITE 120, BUILDING E, LEXINGTON MA 02421
Christopher Rovaldi	officer: Chief Operating Officer	C/O ACCELERON PHARMA INC., 128 SIDNEY ST., CAMBRIDGE MA 02139
Julius Knowles	director	C/O KEROS THERAPEUTICS, INC., 99 HAYDEN AVENUE, SUITE 120, BUILDING E, LEXINGTON MA 02421
Simon Peter Cooper	officer: Chief Medical Officer	C/O KEROS THERAPEUTICS, INC., 99 HAYDEN AVE., BUILDING E, SUITE 120, LEXINGTON MA 02421
Claudia Ordonez	officer: Chief Medical Officer	C/O KEROS THERAPEUTICS, INC., 99 HAYDEN AVENUE, SUITE 120, BUILDING E, LEXINGTON MA 02421
Mary Ann Gray	director	201 W 70TH ST, SUITE 23K, NEW YORK NY 10023
Pontifax Management 4 G.p. (2015) Ltd.	10 percent owner	14 SHENKAR STREET, BEIT OFEK, HERZLIYA PITUACH L3 46140
Tomer Kariv	director, 10 percent owner	C/O ARNO THERAPEUTICS, INC., 200 ROUTE 31 NORTH, SUITE 104, FLEMINGTON NJ 08822
Ran Nussbaum	director, 10 percent owner	C/O KITE PHARMA, INC., 2225 COLORADO AVENUE, SANTA MONICA CA 90404
Orbimed Advisors Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Carl L Gordon	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Jasbir Seehra	director, officer: Chief Executive Officer	C/O ELOXX PHARMACEUTICALS, INC., 950 WINTER STREET, WALTHAM MA 02451
Arkin Bio Ventures Limited Partnership	10 percent owner	6 HACHOSHLIM STREET, HERZLIYA PITUACH L3 4672406